Inmune Bio (INMB) AI Stock Analysis

• Market Cap: $174.96M
• Dividend Yield: N/A
• Average Volume (3M): 265.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: -90.97%
• EPS Growth: -27.47%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -2.13
• Shares Outstanding: 22,930,311
• 10 Day Avg. Volume: 307,784
• 30 Day Avg. Volume: 265,010
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4286.67
• Price to Cash Flow (P/CF): -6.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $23.33
• Price Target Upside: 216.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Inmune Bio's overall stock score reflects significant financial challenges, including declining revenue and ongoing losses. Technical indicators show potential downward momentum, while valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

Positive Factors

Clinical Trials

INMB has implemented a patient enrichment strategy and utilizes a novel clinical endpoint, EMACC, to increase the likelihood of seeing a positive trial.

Market Opportunity

Recessive dystrophic epidermolysis bullosa (RDEB) could represent a $1B opportunity with potential for premium pricing.

Regulatory Approval

The FDA has indicated during a Type C meeting that the data from the study could support a filing.

Negative Factors

Financial Performance

The company ended the period with $20.9M in cash on the balance sheet, which excludes $5.4M raised via ATM; combined, this should provide runway into 2H25 and getting through two key catalysts.

Trial Risks

The large P2b trial testing Xpro in early Alzheimer's patients is expected to read out essentially all meaningful data within 100 days.

Inmune Bio Business Overview & Revenue Model

Company Description

Inmune Bio, Inc. (INMB) is a biotechnology company focused on developing innovative therapies to modulate components of the immune system to treat cancer and neurodegenerative diseases. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary platforms to target innate immune cells. Core products in its pipeline include INKmune, which aims to enhance the ability of natural killer cells to attack cancer, and XPro1595, designed to inhibit neuroinflammation linked to Alzheimer's disease.

How the Company Makes Money

Inmune Bio primarily generates revenue through strategic partnerships, licensing agreements, and potential future sales of its proprietary therapies upon approval. The company may receive upfront payments, milestone payments, and royalties from its collaborative partners. Additionally, Inmune Bio could benefit from government grants and research funding to support its scientific advancements. As its therapies progress through clinical trials and obtain regulatory approvals, commercializing these treatments will be critical for driving significant revenue growth.

Inmune Bio Financial Statement Overview

Summary

Inmune Bio is facing financial challenges with a significant decline in revenue from $77.69 million in 2019 to $14,000 in 2024. Negative net income and EBIT highlight ongoing unprofitability, while margins are severely negative. Despite a strong equity position and manageable debt levels, the ongoing cash burn and revenue decline pose significant risks.

Income Statement

Inmune Bio has shown a significant decline in revenue, with a steep drop from $77.69 million in 2019 to $14,000 in 2024. The company consistently records negative net income and EBIT, highlighting ongoing unprofitability. Margins are severely negative, and the shrinking revenue base raises concerns about future growth prospects.

Balance Sheet

The company maintains a relatively strong equity position with a decreasing debt-to-equity ratio, indicating potential stability in its financial leverage. However, the overall reduction in total assets and equity suggests a diminishing scale of operations, which might affect future growth capabilities.

Cash Flow

Operating cash flows remain negative, reflecting ongoing operational challenges. There was a significant decrease in free cash flow over recent periods, indicating increased cash burn. Positive financing cash flows in some years suggest reliance on external funding to sustain operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
42.00K	14.00K	155.00K	374.00K	181.00K	10.92K
	Gross Profit
42.00K	14.00K	155.00K	374.00K	181.00K	10.92K
	EBIT
-41.55M	-42.63M	-29.74M	-25.95M	-29.15M	-12.23M
	EBITDA
-30.56M	0.00	-29.74M	0.00	0.00	0.00
	Net Income Common Stockholders
-41.27M	42.08M	-30.01M	-28.65M	-30.34M	-12.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
141.66K	20.92M	35.85M	52.15M	74.81M	21.97M
	Total Assets
451.61K	39.56M	57.00M	81.80M	99.94M	40.66M
	Total Debt
350.00K	384.00K	10.44M	15.31M	15.23M	160.16K
	Net Debt
208.34K	-20.54M	-25.41M	-36.84M	-59.58M	-21.81M
	Total Liabilities
600.81K	7.46M	18.86M	21.69M	19.72M	1.90M
	Stockholders Equity
-149.20K	32.10M	38.14M	60.10M	80.22M	38.75M
Cash Flow		Free Cash Flow
-25.75M	-33.36M	-11.98M	-22.69M	-43.50M	-8.94M
	Operating Cash Flow
-25.75M	-33.36M	-11.98M	-22.69M	-28.50M	-8.94M
	Investing Cash Flow
2.55M	0.00	0.00	0.00	-15.00M	0.00
	Financing Cash Flow
17.79M	18.21M	-4.22M	729.00K	96.36M	23.89M

Inmune Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.38
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INMB, the sentiment is Negative. The current price of 7.38 is below the 20-day moving average (MA) of 7.68, below the 50-day MA of 8.29, and above the 200-day MA of 6.78, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 45.72 is Neutral, neither overbought nor oversold. The STOCH value of 31.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INMB.

Inmune Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AXON	78 Outperform	$42.90B	115.36	19.10%	―	33.32%	111.64%
AUPH	70 Outperform	$1.01B	191.97	1.52%	―	33.97%	―
AVXL	62 Neutral	$741.76M	―	-37.72%	―	―	-3.08%
INMB	49 Neutral	$174.96M	―	-119.83%	―	-90.97%	-27.47%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
SAVA	42 Neutral	$57.49M	―	-17.19%	―	―	81.00%
ANVS	38 Underperform	$24.94M	―	-3159.09%	―	―	68.75%

Inmune Bio Corporate Events

Inmune Bio Presents Alzheimer’s Trial Data at Conference

On April 3, 2025, INmune Bio Inc. presented a poster at the International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, detailing the demographics and biomarker status of patients in their MINDFul Phase II trial for early Alzheimer’s disease. The trial, which completed enrollment in November 2024, aims to evaluate the cognitive benefits of XPro1595 in patients with biomarkers of immune dysfunction. Preliminary analyses indicate successful enrollment of a well-characterized cohort, with top-line results expected in June 2025, potentially impacting the company’s positioning in Alzheimer’s treatment development.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score reflects significant financial challenges, including declining revenue and ongoing losses. Technical indicators show potential downward momentum, while valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

INmune Bio Reports Promising Phase I/II Trial Results

INmune Bio Inc. has released preliminary results from a Phase I/II trial of its INKmune therapy, which targets metastatic, castration-resistant prostate cancer by activating NK cells. The trial, which began in March 2025, has shown promising safety and immunologic efficacy, with no serious adverse effects reported after 29 infusions across three dosage levels. The trial aims to determine the effective dose and assess both short- and long-term safety, as well as the therapy’s ability to control tumor burden. The results could enhance INmune Bio’s position in the cancer immunotherapy market and provide significant implications for stakeholders, particularly in terms of advancing cancer treatment options.

Inmune Bio Secures License Agreement for CORDStrom Data

On February 6, 2025, INmune Bio entered a license agreement with Great Ormond Street Hospital NHS Foundation Trust for exclusive commercial use of clinical trial data from the Mission EB study, which investigates CORDStrom’s efficacy in treating pediatric RDEB. This agreement allows INmune Bio to prepare applications for marketing authorization in the US and Europe. The company will provide CORDStrom to UK patients enrolled in ongoing studies and pay milestone fees upon receiving the first marketing authorization. Additionally, INmune Bio announced the termination of its Loan Agreement with Silicon Valley Bank without penalties. The Mission EB study demonstrated CORDStrom’s potential in treating RDEB, leading to plans for filing a Biologics License Application with the FDA and similar applications in Europe. CORDStrom has been granted Rare Pediatric Disease and Orphan Drug designations by the FDA, enhancing its market potential and support for further development.

Inmune Bio Completes Phase 2 Trial for CORDStrom

INmune Bio Inc. announced the completion of a Phase 2 clinical trial for its CORDStrom platform, designed to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. The trial demonstrated that CORDStrom was safe, well-tolerated, and provided clinical benefit, particularly in alleviating itch, a significant problem for RDEB patients. The company is preparing to submit a Biologics License Application to the FDA by the end of 2025, aiming for potential approval and market launch in 2026, which could significantly impact their market positioning and offer a novel treatment option for this unmet medical need.